A. Craig Lockhart - Concepedia

Author

A. Craig Lockhart

Also Known As

A C Lockhart, A Craig Lockhart, A Lockhart, A. C. Lockhart, A. Craig Lockhart, A. Lockhart, A.C. Lockhart, Albert C. Lockhart, Albert Craig Lockhart, Albert Lockhart

127

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

University of Miami Sylvester Comprehensive Cancer Center Millennium Engineering and Integration (United States)Sarah Cannon Washington University in St. Louis

About

A. Craig Lockhart is an author at University of Miami specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	398
2	Health Sciences	2	2	62
3	Cell Biology	2	2	99
4	Biomedical Engineering	1	1	29
5	Biostatistics	1	1	14

A. Craig Lockhart

Publications

Citations

H-Index

Page 1

	Year	Citations
Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis Eli L. Diamond, Vivek Subbiah, A. Craig Lockhart, JAMA Oncology	2017	395
BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET Study Thomas Kaley, Mehdi Touat, Vivek Subbiah, Journal of Clinical Oncology	2018	317
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors A. Craig Lockhart, Mace L. Rothenberg, Jakob Dupont, Journal of Clinical Oncology	2009	235
Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression Jessica Silva-Fisher, Ha X. Dang, Nicole M. White, Nature Communications	2020	127
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> V600-Mutant Non-Melanoma Cancers Vivek Subbiah, Igor Puzanov, Jean‐Yves Blay, Cancer Discovery	2020	120
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. A. Craig Lockhart, Rod D. Braun, Daohai Yu, PubMed	2003	90
Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1 Lihong Wang-Bishop, Zheng Chen, Ahmed R. Gomaa, Gastroenterology Activated KrasChemoprevention StrategyGastrointestinal OncologyAurka Reduces ProliferationMedicine	2018	87
The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study Kenneth R. Hande, A. Hagey, Jordan Berlin, Clinical Cancer Research	2006	81
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors A. Craig Lockhart, Todd M. Bauer, Charu Aggarwal, Investigational New Drugs	2018	73
Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors Jakob Dupont, Mace L. Rothenberg, David R. Spriggs, Journal of Clinical Oncology Vegf TrapIntravenous Vegf TrapAnti-vegf Trap AntibodiesPathologyPharmacotherapy	2005	66

Page 1